Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Obexelimab by Zenas BioPharma (USA) for Immunoglobulin G4-Related Disease (IgG4-RD): Likelihood of Approval
Obexelimab is under clinical development by Zenas BioPharma (USA) and currently in Phase III for Immunoglobulin G4-Related Disease (IgG4-RD). According...
Data Insights
Obexelimab by Zenas BioPharma (USA) for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
Obexelimab is under clinical development by Zenas BioPharma (USA) and currently in Phase III for Acquired (Autoimmune) Hemolytic Anemia. According...